Quantcast
Last updated on April 16, 2014 at 7:58 EDT

Patented Allogeneic Bone Gel(TM) for Sale from ICAP Patent Brokerage

September 25, 2013

NEW YORK, Sept. 25, 2013 /PRNewswire/ — ICAP Patent Brokerage announces for sale an innovative low inflammatory demineralized bone material – Allogeneic Bone Gel(TM) – for orthopedic applications from PlusLife® (formerly Perth Bone and Tissue Bank). PlusLife is a leading provider of high quality grafting materials for surgical treatment, and their novel demineralized bone material (DBM) has been cultivated through many years of research and studies.

(Logo: http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

“The treatment of bone ailments and injuries provides unique challenges for orthopedic surgeons across the veterinary and human fields. This portfolio is highly relevant to the pharmaceutical and medical fields as the patented Allogeneic Bone Gel(TM) provides key advancements for surgical techniques such as bone grafting, fracture repair, and dental conditions,” says Dean Becker, CEO of ICAP Patent Brokerage.

Key Characteristics & Benefits
The processes for producing traditional DBM result in a product that reduces beneficial growth factors and can cause inflammation, which leads to bone loss and orthopedic surgery failure. The patent portfolio covers a superior form of DBM and methods for its production.

PlusLife has developed a process for producing DBM-like material that provides the same level of mechanical properties as traditional DBM products, but which allows more of the naturally occurring growth factors to remain active. These growth factors in turn stimulate the growth of bone forming cells. The product, Allogeneic Bone Gel(TM), can be used in all of the normal orthopedic uses that traditional DBM products have been used, while providing a better biological support for implanting or infiltrating bone-forming cells and without the associated inflammatory issues.

A number of animal studies have been carried out, which demonstrate that Allogeneic Bone Gel(TM) is capable of producing vertebral fusion in the lumbar spine. Further studies have shown that the innovative material is a good carrier for autologous bone marrow cells, which induces spinal fusion and demonstrates new bone formation.

Find the detailed research findings and technical description of the patented Allogeneic Bone Gel(TM) IP sales offering.

To learn more about the assets available for sale in this portfolio:
Contact Paul Greco of ICAP Patent Brokerage at (212) 815-6692 or via email at Paul.Greco@us.icap.com.

Follow us on Twitter (@ICAP_Auction_IP) and join our LinkedIn group.

About ICAP Patent Brokerage
ICAP Patent Brokerage is a division of ICAP plc and the world’s largest intellectual property brokerage and patent auction firm.

About ICAP
ICAP is a leading markets operator and provider of post trade risk mitigation and information services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, FX, emerging markets and equity derivatives through voice and electronic networks. Through its post trade risk mitigation and information services ICAP helps customers manage and mitigate risks in their portfolios. For more information, go to www.icap.com.

About PlusLife®
PlusLife® was established under the name The Perth Bone & Tissue Bank (PBTB) in 1992. It is the only bone bank in Western Australia and operates from Hollywood Private Hospital Campus. In June 2013 the organization changed its name to PlusLife. PlusLife’s business focus is enhance the retrieval, testing, storage, processing and transplantation of bone and tissue grafts; and importantly, to ensure that ongoing research and technological achievements continue to be a key platform of the work the organization undertakes. For more information, go to www.perthbonebank.com.

SOURCE ICAP Patent Brokerage


Source: PR Newswire